Document 0157
 DOCN  M9590157
 TI    Response to podophyllotoxin treatment of genital warts in relation to
       HIV-1 infection among patients in Dar es Salaam, Tanzania.
 DT    9509
 AU    Kilewo CD; Urassa WK; Pallangyo K; Mhalu F; Biberfeld G; Wigzell H;
       Department of Obstetrics/Gynaecology, Muhimbili University; College of
       Health Sciences, Dar es Salaam, Tanzania.
 SO    Int J STD AIDS. 1995 Mar-Apr;6(2):114-6. Unique Identifier : AIDSLINE
       MED/95298892
 AB    Forty-two Tanzanian patients with genital warts were treated with 0.5%
       podophyllotoxin solution (Wartec) for 3 days. Thirteen patients (30.9%)
       were cured and a further 7 patients (16.7%) had more than 50% of lesions
       cleared at 6 weeks, while 19 patients were resistant to treatment. Three
       patients had a recurrence of lesions after an initial response.
       Thirty-three patients were tested for serological evidence of infection
       with human immunodeficiency virus (HIV) and 15 (45.5%) patients were
       shown to be HIV-1 antibody positive. The response to treatment was
       analysed in relation to HIV antibody status. The cure rate was
       significantly higher in HIV seronegative patients (8/18 = 44.4%)
       compared to HIV seropositive patients (1/15 = 6.7%) (P = 0.018). We
       conclude that podophyllotoxin treatment provides a useful non-hospital
       based treatment for genital warts, but HIV infection appears to
       contribute to the failure of treatment for genital warts.
 DE    Adolescence  Adult  Child  Condylomata Acuminata/COMPLICATIONS/*DRUG
       THERAPY  Female  Human  HIV Infections/*COMPLICATIONS  *HIV-1  Male
       Podophyllotoxin/*THERAPEUTIC USE  Support, Non-U.S. Gov't  Tanzania
       Treatment Outcome  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).